GT Biopharma, Inc. - FORM 10-K - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - March 31, 2017

Attached files

file filename
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc.oxis_ex322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.oxis_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.oxis_ex311.htm
10-K - ANNUAL REPORT - GT Biopharma, Inc.oxis_10k.htm
 
Exhibit 32.1
 
CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Anthony Cataldo, Chief Executive Officer of OXIS International, Inc. (the “Company”), hereby certify that, to the best of my knowledge:
 
(i) the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
 
 
 
 
 
 
 
Date: March 31, 2017
By:
/s/ Anthony Cataldo
 
 
 
Name: Anthony Cataldo
 
 
 
Title: Chief Executive Officer, Chairman and Director (Principal Executive Officer)
 
 
 

Stock widget

Investing forum

GT Biopharma, Inc. Reports